Scleroderma

General Scleroderma Information - Provided by MedlinePlus.gov

Currently Enrolling ACE Scleroderma Clinical Trials

~  Rituximab for Treatment of SSc-PAH (ASC01) ~

     ASC01 will soon begin enrolling subjects. Please contact your nearest site's principal investigator or clinical trial coordinator for more information.

• University of Colorado Health Sciences Center (Aurora): Dr. David Badesch at 720.848.6567 or Deb McCollister at 720.848.6540
• University of Alabama at Birmingham: Dr. Barri Fessler at 205.934.2813 or Randall Parks at 205.934.7754
• Feinstein Institute for Medical Research (Manhasset, NY): Dr. Meggan Mackay at 516.562.3838 or Andrew Shaw at 516.562.2591
• Duke University Medical Center (Durham, NC): Dr. Victor Tapson at 919.668.0325 or Marguerite Thoma at 919.668.1770
• University of Pittsburgh Medical Center (PA): Dr. Thomas Medsger at 412.648.1897 or Dana Ivanco at 412.647.6000
• University of Rochester Medical Center (NY): Dr. Jim White at 585.486.0960 x123 or Antonia Heininger at 585.486.0147
• Thomas Jefferson University (Philadelphia, PA): Dr. Sandra Weibel at 215.955.0830 or Elizabeth Grace at 215.955.5778
• Stanford University (Palo Alto, CA): Dr. Mark Nicolls at 650.493.5000 x69289 or Val Scott at 650.725.8082
• Virginia Commonwealth University (Richmond): Dr. Daniel Grinnan at 804.828.9072 or Chris DeWilde at 804.628.5710
• Johns Hopkins University (Baltimore, MD): Dr. Paul Hassoun at 410.614.6311 or Dr. Sukhminder Singh at 410.614.1316
• Allegheny General Hospital (Pittsburgh, PA): Dr. Srinivas Murali at 412.359.3527 or Kate Pacek at 412.358.3291
• University of Texas Southwestern (Dallas, TX): Dr. Fernando Torres at 214.645.6487 or Mary Ann Byerly at 214.645.6005